Colorcon starts No-Tox ink manufacturing at new UK facility
The additional capacity will provide customers with shorter lead times and reduced transportation costs.
Colorcon No-Tox Products, a leader in the design and manufacture of FDA and EU regulatory compliant specialty printing inks for direct and indirect contact with food, medical devices and pharmaceutical products has opened a new UK-based manufacturing facility to serve its growing customer base in Europe, the Middle East and Africa (EMEA).
With this new manufacturing capacity, Colorcon No-Tox is strengthening its presence in the European and UK markets and will provide its customers with shorter lead times and reduced transportation costs.
“We are excited to announce this important next step in our strategy to become an integral part of our customers’ supply chains,” said Simon Tasker, President, Colorcon Americas.
“Our new No-Tox plant in the UK, which is an extension of our existing pharmaceutical manufacturing plant in Dartford will allow us to serve our customers in increasingly better and more efficient ways by providing our high-quality regulatory compliant inks and coatings with close proximity to their markets and at lower transportation costs.”
David Bain, Managing Director, Colorcon Ltd added: “Our regional team is looking forward to supporting this next stage in the strategic market expansion of our Colorcon No-Tox specialty printing ink business. The plant will initially focus on regulatory compliant inks and coatings for direct and indirect food contact applications; such as those widely used in the plastic to paper straw conversion. The addition of medical and pharmaceutical inks and coatings will be extended through 2020.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.